Eli Lilly and Co. is discontinuing development of tabalumab being studied for the treatment of systemic lupus erythematosus (SLE, commonly known as lupus), due to insufficient efficacy in two Phase III trials. The decision was not based on safety concerns.   In the ILLUMINATE 1 study, tabalumab did not achieve the primary endpoint, at either dose studied, of statistically significant improvement of lupus disease activity compared to standard of care therapy. In ILLUMINATE 2, the higher dose of t...